Eyewire+Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in US

⚠️ Early Stage / Preclinical Research

Bausch + Lomb has launched PreserVision AREDS3 nationally, combining the NEI-recommended AREDS2 nutrient profile with a proprietary B-vitamin complex (B1, B2, B3, B5, B6, B7, B9, B12). The company positions the formulation as extending nutritional support to earlier AMD stages, with national retail availability at Amazon, Target, Walgreens, and Walmart.

Drug Status

• This is an OTC dietary supplement, not an FDA-approved drug.
• The AREDS2 component carries established evidence for reducing progression from moderate to advanced AMD.
• The B-vitamin addition is supported by a 2025 narrative review in Ophthalmology and Therapy summarizing associations across approximately 30,000 participants in more than 20 human studies, including some randomized trial data.
• Bausch + Lomb states a long-term RCT of the AREDS3 formulation itself is planned but has not been initiated or completed.

What Changes / What Stays the Same

• AREDS2 supplementation guidance from the NEI remains unchanged.
• The AREDS3 launch extends the product line and broadens the company’s recommended use population to include earlier-stage AMD, though no guideline body has yet endorsed this expanded indication.
• Eye care professionals may encounter patient questions about the new formulation and whether it warrants a switch from standard AREDS2 products.

Watch For

• Results from the planned AREDS3 long-term clinical trial will be the meaningful efficacy signal. Until that data is available, the B-vitamin component remains associational.
• Professional society commentary from the American Academy of Ophthalmology on the expanded use framing would clarify whether guideline-level support follows the launch.